Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMRT with Capecitabine and Mitomycin C for Anal Cancer
NCT03381352Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Dec 2015
- Primary completion
- Dec 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, mitomycin c in anal squamous cell carcinoma (SCCA), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
capecitabinemitomycin c
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT03381352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381352.